The Journal of Practical Medicine >
Expression changes of heat shock protein B-1 in myocardial injury and its regulatory effect on the maturation process of TGF-β1
Received date: 2026-04-02
Online published: 2026-08-05
Objective To investigate the expression changes of heat shock protein beta-1 (HSPB1) during myocardial injury and its regulatory role in the maturation process of transforming growth factor-β1 (TGF-β1). Methods Publicly accessible cardiac single-cell transcriptomic datasets, an isoproterenol (ISO)-induced mouse myocardial injury model, and H9c2 cell experiments were integrated to evaluate the expression changes of HSPB1. The overexpression of HSPB1 and the Cys137 mutation were employed to assess their impacts on pro-TGF-β1, mature TGF-β1, and the Smad signaling pathway. Molecular docking and bidirectional co-immunoprecipitation (Co-IP) assays were carried out to analyze the interaction between HSPB1 and pro-TGF-β1. Results Public cardiac single-cell transcriptomic data have demonstrated that HSPB1 is expressed in multiple cardiac cell populations, with relatively higher expression levels in cardiomyocytes. In comparison with the control group, ISO treatment led to a reduction in the left ventricular ejection fraction (LVEF) in mice from (95.20 ± 2.82)% to (82.28 ± 3.05)% and (63.18 ± 4.20)%, as well as a decrease in the left ventricular fractional shortening (LVFS) from (69.45 ± 8.32)% to (48.66 ± 3.16)% and (38.32 ± 2.23)% (all P < 0.001). This was accompanied by aggravated myocardial fibrosis and cardiomyocyte hypertrophy. Immunohistochemistry and Western blot analyses indicated that HSPB1 expression was significantly up-regulated in myocardial tissue after 14 days of ISO treatment (P = 0.000 4 and P < 0.000 1, respectively). H9c2 cell experiments revealed that, under ISO stimulation, overexpression of wild-type HSPB1 (HSPB1-WT) increased pro-TGF-β1 levels, while reducing the mature TGF-β1/pro-TGF-β1 ratio, partially decreasing mature TGF-β1 levels, and lowering p-Smad2/3 levels (vs. ISO group, P = 0.037 5, 0.049 9, and 0.002 1, respectively). These effects were markedly attenuated in the Cys137 mutant, with related indicators significantly elevated compared with the HSPB1-WT group (P = 0.000 1, 0.001 8, and 0.000 6, respectively). Molecular docking analysis suggested a potential interaction interface between HSPB1 and pro-TGF-β1. Bidirectional Co-IP further confirmed the interaction between the two proteins, whereas the Cys137 mutation weakened their binding signal. Conclusions HSPB1 may interact with pro-TGF-β1 via its redox-sensitive residue Cys137 and participate in restricting its excessive maturation process, thus modulating the TGF-β1/Smad signaling activity. This study offers a novel molecular perspective for comprehending the fine-tuned regulation of myocardial fibrosis-related signaling pathways.
Daqing DENG , Juan ZHOU , Jia WANG , Yiqun LIU , Keqin CHEN , Lin ZHOU , Xiehong LIU . Expression changes of heat shock protein B-1 in myocardial injury and its regulatory effect on the maturation process of TGF-β1[J]. The Journal of Practical Medicine, 2026 , 42(14) : 2477 -2487 . DOI: 10.3969/j.issn.1006-5725.2026.14.001
| [1] | 中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3): 235-275. doi:10.3760/cma.j.cn112148-20231101-00405 . |
| [2] | PESCE M, DUDA G N, FORTE G, et al. Cardiac fibroblasts and mechanosensation in heart development, health and disease[J]. Nat Rev Cardiol, 2023, 20(5): 309-324. doi:10.1038/s41569-022-00799-2 . |
| [3] | FRANGOGIANNIS N G. Transforming growth factor-β in myocardial disease[J]. Nat Rev Cardiol, 2022, 19(7): 435-455. doi:10.1038/s41569-021-00646-w . |
| [4] | VISTNES M. Hitting the target! challenges and opportunities for TGF-β inhibition for the treatment of cardiac fibrosis[J]. Pharmaceuticals, 2024, 17(3): 267. doi:10.3390/ph17030267 . |
| [5] | ZHAO M, WANG L, WANG M, et al. Targeting fibrosis, mechanisms and cilinical trials[J]. Signal Transduct Target Ther, 2022, 7(1): 206. doi:10.1038/s41392-022-01070-3 . |
| [6] | SHI M, ZHU J, WANG R, et al. Latent TGF-β structure and activation[J]. Nature, 2011, 474(7351): 343-349. doi:10.1038/nature10152 . |
| [7] | JIN M, SEED R I, SHING T, et al. Latent-TGF-β has a domain swapped architecture[J]. Nat Commun, 2025, 16: 10469. doi:10.1038/s41467-025-65465-w . |
| [8] | GAN B. Redox-driven cell death by disulfidptosis and its therapeutic potential[J]. Nat Rev Mol Cell Biol, 2025, 26(10): 727-729. doi:10.1038/s41580-025-00888-3 . |
| [9] | LIU X, NIE L, ZHANG Y, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis[J]. Nat Cell Biol, 2023, 25(3): 404-414. doi:10.1038/s41556-023-01091-2 . |
| [10] | DENG Z, FAN T, XIAO C, et al. TGF-β signaling in health, disease and therapeutics[J]. Signal Transduct Target Ther, 2024, 9: 61. doi:10.1038/s41392-024-01764-w . |
| [11] | JIN M, SEED R I, CAI G, et al. Dynamic allostery drives autocrine and paracrine TGF-β signaling[J]. Cell, 2024, 187(22): 6200-6219.e23. doi:10.1016/j.cell.2024.08.036 . |
| [12] | GU J, HE Y, HE C, et al. Advances in the structures, mechanisms and targeting of molecular chaperones[J]. Signal Transduct Target Ther, 2025, 10: 84. doi:10.1038/s41392-025-02166-2 . |
| [13] | ADRIAENSSENS E, ASSELBERGH B, RIVERA-MEJíAS P, et al. Small heat shock proteins operate as molecular chaperones in the mitochondrial intermembrane space[J]. Nat Cell Biol, 2023, 25(3): 467-480. doi:10.1038/s41556-022-01074-9 . |
| [14] | WANG N, LIU X, LIU K, et al. Homo-oxidized HSPB1 protects H9c2 cells against oxidative stress via activation of KEAP1/NRF2 signaling pathway[J]. iScience, 2023, 26(8): 107443. doi:10.1016/j.isci.2023.107443 . |
| [15] | PETERS C, HASLBECK M, BUCHNER J. Catchers of folding gone awry: A tale of small heat shock proteins[J]. Trends Biochem Sci, 2024, 49(12): 1063-1078. doi:10.1016/j.tibs.2024. 08.003 . |
| [16] | BERKELEY R F, PLONSKI A P, PHAN T M, et al. Capturing the conformational heterogeneity of HSPB1 chaperone oligomers at atomic resolution[J]. J Am Chem Soc, 2025, 147(18): 15181-15194. doi:10.1021/jacs.4c18668 . |
| [17] | SLUZALA Z B, HAMATI A, FORT P E. Key role of phosphorylation in small heat shock protein regulation via oligomeric disaggregation and functional activation[J]. Cells, 2025, 14(2): 127. doi:10.3390/cells14020127 . |
| [18] | SUN Z, BRODSKY J L. Protein quality control in the secretory pathway[J]. J Cell Biol, 2019, 218(10): 3171-3187. doi:10.1083/ jcb.201906047 . |
| [19] | 李霞, 李映, 何伟, 等. 糖蛋白130在急性肝损伤中负性调控内质网应激作用及机制[J]. 实用医学杂志, 2022, 38(12): 1499-1505. doi:10.3969/j.issn.1006-5725.2022.12.011 . |
| [20] | LI C, MENG X, WANG L, et al. Mechanism of action of non-coding RNAs and traditional Chinese medicine in myocardial fibrosis: Focus on the TGF-β/Smad signaling pathway[J]. Front Pharmacol, 2023, 14: 1092148. doi:10.3389/fphar.2023. 1092148 . |
| [21] | WANG G, JIAO H, ZHENG J N, et al. HSP27 regulates TGF-β mediated lung fibroblast differentiation through the Smad3 and ERK pathways[J]. Int J Mol Med, 2017, 39(1): 183-190. doi:10.3892/ijmm.2016.2813 . |
| [22] | 王乙安, 宴玥, 赵恒, 等. 腹膜纤维化大鼠模型构建及其腹膜组织中热休克蛋白的表达变化[J]. 山东医药, 2017, 57(37): 25-28. doi:10.3969/j.issn.1002-266X.2017.37.008 . |
| [23] | ZOU Y, SHI H, LIU N, et al. Mechanistic insights into heat shock protein 27, a potential therapeutic target for cardiovascular diseases[J]. Front Cardiovasc Med, 2023, 10: 1195464. doi:10.3389/fcvm.2023.1195464 . |
| [24] | WANG Y, LIU J, KONG Q, et al. Cardiomyocyte-specific deficiency of HSPB1 worsens cardiac dysfunction by activating NFκB-mediated leucocyte recruitment after myocardial infarction[J]. Cardiovasc Res, 2019, 115(1): 154-167. doi:10.1093/cvr/cvy163 . |
| [25] | CAMPBELL M G, CORMIER A, ITO S, et al. Cryo-EM reveals integrin-mediated TGF-β activation without release from latent TGF-β[J]. Cell, 2020, 180(3): 490-501.e16. doi:10.1016/j.cell.2019.12.030 . |
| [26] | RIFKIN D B. Latent transforming growth factor-β (TGF-β) binding proteins: Orchestrators of TGF-β availability[J]. J Biol Chem, 2005, 280(9): 7409-7412. doi:10.1074/jbc.R400029200 . |
| [27] | SACHAN N, PHOON C K L, BU L, et al. Binding requirements for latent transforming growth factor Beta2 activation[J]. Matrix Biol Plus, 2024, 22: 100149. doi:10.1016/j.mbplus.2024. 100149 . |
| [28] | MU D, CAMBIER S, FJELLBIRKELAND L, et al. The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1[J]. J Cell Biol, 2002, 157(3): 493-507. doi:10.1083/jcb.200109100 . |
| [29] | ROBERTSON I B, RIFKIN D B. Regulation of the bioavailability of TGF-β and TGF-β-related proteins[J]. Cold Spring Harb Perspect Biol, 2016, 8(6): a021907. doi:10.1101/cshperspect.a021907 . |
| [30] | KANAMORI M, SATO I, KOO C X, et al. Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety[J]. Commun Med, 2026, 6: 131. doi:10.1038/s43856-026-01408-w . |
| [31] | DUBOIS C M, BLANCHETTE F, LAPRISE M H, et al. Evidence that furin is an authentic transforming growth factor-β1-converting enzyme[J]. Am J Pathol, 2001, 158(1): 305-316. doi:10.1016/S0002-9440(10)63970-3 . |
| [32] | 安靖雯, 冯俊云, 饶磊, 等. 细胞衰老与瘢痕纤维化的关系研究进展[J]. 实用医学杂志, 2024, 40(12): 1749-1754. doi:10.3969/j.issn.1006-5725.2024.12.023 . |
/
| 〈 |
|
〉 |